Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
复制标题
DOI：
10.1016/j.vaccine.2014.04.036
复制
发表时间：
2014-06-17
期刊：
影响因子：
5.5
通讯作者：
Castillo-Olivares, Javier
中科院分区：
文献类型：
--
作者：
Alberca, Berta;Bachanek-Bankowska, Katarzyna;Cabana, Marta;Calvo-Pinilla, Eva;Viaplana, Elisenda;Frost, Lorraine;Gubbins, Simon;Urniza, Alicia;Mertens, Peter;Castillo-Olivares, Javier
构建了表达非洲马病病毒9型VP2的重组改良痘苗病毒安卡拉病毒。分别在第0天和第20天对4匹马进行免疫，并设3匹未接种的对照组。实验第34天，接种AHSV-9107.4TCID50疫苗的马匹和对照马尾静脉注射AHSV-9疫苗。在挑战中，疫苗接种者有病毒中和抗体，但对AHSV-VP7抗体为阴性。所有接种的疫苗都完全预防了非洲马病的临床症状。非洲马病病毒(AHSV)是一种由节肢动物传播的病原体，可感染所有种类的马科动物，并导致马的高死亡率。此前，表达AHSV4型VP2蛋白的重组改良安卡拉痘苗病毒被证明能在马身上诱导病毒中和抗体，并保护干扰素α受体基因敲除小鼠(IFNAR−/−)免受强毒攻击。这项研究建立在先前工作的基础上，检测了MVA-VP2疫苗在AHSV感染的自然宿主中的保护效果。用表达AHSV 9型主要衣壳蛋白(VP2)的重组MVA病毒对4匹马进行两次免疫，然后用AHSV-9强毒株攻击接种的动物和未接种疫苗的对照组。通过标准终点稀释法测定，接种疫苗的动物完全免受临床疾病和病毒血症的影响。相比之下，所有对照马在攻击后都出现了病毒血症，并死于感染。这些结果表明，表达AHSV外衣壳VP2的重组MVA病毒在野外可作为AHSV感染的保护性疫苗。
A recombinant modified Vaccinia Ankara virus expressing VP2 of African horse sickness virus serotype 9 was generated. Four horses were vaccinated on days 0 and 20. Three unvaccinated controls were used. Vaccinated and control horses were challenged intravenously with 107.4TCID50 of AHSV-9 on day 34 of the study. At challenge, vaccinates had virus neutralising antibodies but were negative for antibodies to AHSV-VP7. All vaccinates were completely protected against clinical signs of African horse sickness. African horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species of equidae and causes high mortality in horses. Previously, a recombinant modified vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 was shown to induce virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR −/−) against virulent AHSV challenge. This study builds on the previous work, examining the protective efficacy of MVA-VP2 vaccination in the natural host of AHSV infection. A study group of 4 horses was vaccinated twice with a recombinant MVA virus expressing the major capsid protein (VP2) of AHSV serotype 9. Vaccinated animals and a control group of unvaccinated horses were then challenged with a virulent strain of AHSV-9. The vaccinated animals were completely protected against clinical disease and also against viraemia as measured by standard end-point dilution assays. In contrast, all control horses presented viraemia after challenge and succumbed to the infection. These results demonstrate the potential of recombinant MVA viruses expressing the outer capsid VP2 of AHSV as a protective vaccine against AHSV infection in the field.
登录
查看更多内容
DOI：
10.1016/0147-9571(94)90047-7
发表时间：
1994-08-01
影响因子：
2
作者：
BURRAGE, TG;LAEGREID, WW
通讯作者：
LAEGREID, WW
影响因子：
5.5
作者：
Guthrie, Alan J.;Quan, Melvyn;MacLachlan, N. James
通讯作者：
MacLachlan, N. James
影响因子：
3.7
作者：
StoneMarschat, MA;Moss, SR;Laegreid, WW
通讯作者：
Laegreid, WW
影响因子：
3.1
作者：
Quan, M.;Lourens, C. W.;Guthrie, A. J.
通讯作者：
Guthrie, A. J.
影响因子：
3.7
作者：
Schaefer-Klein, J;Givol, I;Hughes, SH
通讯作者：
Hughes, SH